Halozyme Therapeutics Inc. (HALO)
Halozyme Therapeutics (HALO) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Besides Wall Street's top-and-bottom-line estimates for Halozyme Therapeutics (HALO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.
Halozyme Therapeutics: The Royalty Engine Is Becoming A Drug-Delivery Toll Road
Halozyme (HALO) is evolving from an ENHANZE royalty story into a diversified subcutaneous drug delivery platform, expanding its technology suite and partner base. FY 2025 royalty revenue surged 52% to $867.8M; 2026 guidance calls for 30–35% royalty growth and adjusted EBITDA of $1.125–$1.205B. Recent acquisitions (Hypercon, Surf Bio) and new partnerships (Vertex, Takeda) extend HALO's IP runway and position it as a one-stop biologic delivery solutions provider.
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Goldman's HALO Trade Could Be the 2026 Edge Investors Are Missing
Goldman Sachs (NYSE:GS) has a pretty interesting strategy for investors who aren't yet comfortable braving the dip in some of the hardest-hit stocks, specifically in tech.
Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
HALO Helps, But Dividend Investors Still Need to Be Selective
The latest buzz acronym in the investment community, spurred in part by the artificial intelligence (AI) trade, is HALO, or “heavy assets, low obsolescence.” The catchy acronym is relevant to dividend investors because many of the companies in the hard assets realm are dividend payers.
Aquatic Capital Management LLC Acquires Shares of 89,651 Halozyme Therapeutics, Inc. $HALO
Aquatic Capital Management LLC bought a new position in Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought 89,651 shares of the biopharmaceutical company's stock, valued at approximately $6,575,000. Aquatic Capital Management LLC owned about 0.08% of Halozyme Therapeutics as
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of “Hold” by Brokerages
Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) has earned an average rating of "Hold" from the twelve ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating on the company.
Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Can AST SpaceMobile's HALO Contract Strengthen Its Defense Footprint?
ASTS lands a $30 million Space Development Agency contract to deploy BlueBird LEO satellites, advancing direct-to-device defense communications.
